Potential therapeutic effects of Neurotrophin on acute and chronic urological diseases

Hu Yanhui

Neurotrophin Nerve Growth Factor (NT) (NGF), Brain-Derived Neurotrophic Factor (BDNF), NT-3, and NT-4/5 are proteins that regulate proliferation, differentiation, and proliferation. Cell survival in the developing and mature Central Nervous System (CNS) by binding to two types of receptors, the Trk and p75 NTR receptors. Driven by the growth-promoting and survival-promoting effects of these proteins, many studies have attempted to use exogenous NT to prevent neuronal disease-associated cell death or promote regeneration of cells. The axon is broken due to mechanical trauma. . Indeed, such neurological effects have been demonstrated repeatedly in animal models of stroke, nerve damage, and neurodegenerative disease. However, limitations, including the short biological half-life and low blood-brain permeability of these proteins, preclude their conventional application to the treatment of human disease. In this report, we review the evidence for the neuroprotective effects of NT in animal models, highlight outstanding technical challenges, and discuss more recent attempts to exploit this potential. Neuroprotective effects of endogenous NT using small molecules and cell transplantation. Preclinical research over the past 3 decades has detailed the signaling pathways leading to neuronal cell death. In addition, numerous neuroprotective strategies have been developed to improve brain injury and preserve or restore neurological function in animal models of stroke, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Huntington’s Disease (HD) and other neurological disorders. These treatments include the use of neurotrophic factors, which are endogenous proteins required for proliferation, differentiation, and survival during development and neuroplasticity throughout life. Indeed, supplying the brain with exogenous neurotrophic factors, such as Neurotrophin Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), can 60-90% reduction in infarct volume with almost complete recovery stroke.